Literature DB >> 8827372

Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience.

A Cao1, M C Rosatelli, R Galanello.   

Abstract

Homozygous beta-thalassaemia in a number of at-risk populations (Greek and Turkish Cypriots, Greeks, Continental Italians and Sardinians) has been prevented at the population level by programmes based on carrier screening, genetic counselling and prenatal diagnosis. The Sardinian experience is based on a 20-year programme. Voluntary screening has been offered to prospective parents and, primarily, to women with an ongoing pregnancy. Education of the population at large, training of health personnel, and use of posters and informative booklets have been critical elements for the success of the programme. Genetic counselling has been carried out in a non-directive manner following well-established guidelines. The use of extended family screening magnified the efficacy of the screening programme, allowing the identification of the large majority of parents at risk by screening only 13% of the population at child-bearing age. Following counselling, the large majority of parents accepted prenatal diagnosis. Definition of the parents' mutation and prenatal diagnosis were carried out by a number of PCR-based procedures. The programme was effective, as indicated by the reduction of the birth rate of thalassaemia major from 1:250 live births to 1:4000.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827372     DOI: 10.1002/9780470514887.ch8

Source DB:  PubMed          Journal:  Ciba Found Symp        ISSN: 0300-5208


  15 in total

Review 1.  Carrier screening for beta-thalassaemia: a review of international practice.

Authors:  Nicole E Cousens; Clara L Gaff; Sylvia A Metcalfe; Martin B Delatycki
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

2.  Prevention of sickle cell disease: observations on females with the sickle cell trait from the Manchester project, Jamaica.

Authors:  Karlene Mason; Felicea Gibson; Ruth-Ann Gardner; Beryl Serjeant; Graham R Serjeant
Journal:  J Community Genet       Date:  2015-12-02

3.  Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications.

Authors:  Saqib H Ansari; Tahir S Shamsi; Mushtaq Ashraf; Muneera Bohray; Tasneem Farzana; Mohammed Tahir Khan; Kousar Perveen; Sajida Erum; Iqra Ansari; Muhammad Nadeem; Masood Ahmed; Faizan Raza
Journal:  Int J Mol Epidemiol Genet       Date:  2011-11-28

4.  Cascade screening for beta-thalassemia: A practical approach for identifying and counseling carriers in India.

Authors:  Ajit C Gorakshakar; Roshan B Colah
Journal:  Indian J Community Med       Date:  2009-10

5.  Frequency of β-thalassemia trait and other hemoglobinopathies in northern and western India.

Authors:  Nishi Madan; Satendra Sharma; S K Sood; Roshan Colah; Late H M Bhatia
Journal:  Indian J Hum Genet       Date:  2010-01

Review 6.  The prevention of thalassemia.

Authors:  Antonio Cao; Yuet Wai Kan
Journal:  Cold Spring Harb Perspect Med       Date:  2013-02-01       Impact factor: 6.915

7.  Carrier Screening for β Thalassemia in Pregnant Indian Women: Experience at a Single Center in Madhya Pradesh.

Authors:  Asha Baxi; Kaushal Manila; Pooja Kadhi; Baxi Heena
Journal:  Indian J Hematol Blood Transfus       Date:  2012-06-22       Impact factor: 0.900

8.  Molecular epidemiology of β-thalassemia in Pakistan: Far reaching implications.

Authors:  Saqib H Ansari; Tahir S Shamsi; Mushtaq Ashraf; Tasneem Farzana; Muneera Bohray; Kousar Perveen; Sajida Erum; Iqra Ansari; Muhammad Nadeem Ahmed; Masood Ahmed; Faizan Raza
Journal:  Indian J Hum Genet       Date:  2012-05

Review 9.  Invasive & non-invasive approaches for prenatal diagnosis of haemoglobinopathies: experiences from India.

Authors:  R B Colah; A C Gorakshakar; A H Nadkarni
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

10.  Causes of new cases of major thalassemia in sistan and balouchistan province in South-East of iran.

Authors:  E Miri-Moghaddam; M Naderi; S Izadi; Ma Mashhadi
Journal:  Iran J Public Health       Date:  2012-11-01       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.